Silodosin - Allergan/Kissei Pharmaceutical/Recordati

Drug Profile

Silodosin - Allergan/Kissei Pharmaceutical/Recordati

Alternative Names: KAD 3213; KMD-3213; KSO-0400; Rapaflo; Silodyx; Thrupas; Urief; Urief OD; Urorec

Latest Information Update: 15 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kissei Pharmaceutical
  • Developer Actavis; Allergan; Almirall S.A.; Daiichi Sankyo Company; Eisai Co Ltd; JW Pharmaceutical; Kissei Pharmaceutical; Mayne Pharma Group; Pharmaplan; Recordati; Synmosa Biopharma; Zambon France
  • Class Benzamides; Indoles; Muscle relaxants; Small molecules
  • Mechanism of Action Alpha-1a adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Benign prostatic hyperplasia
  • Phase II Urinary calculi
  • Clinical Phase Unknown Nocturia
  • No development reported Prostatitis

Most Recent Events

  • 01 Oct 2018 JW Pharmaceutical plans a clinical trial for Overactive bladder (Combination therapy, In adults, In the elderly) in South Korea (2018AS0141; KCT0003202)
  • 15 Sep 2017 Launched for Benign prostatic hyperplasia in Australia (PO)
  • 23 May 2017 Registered for Benign prostatic hyperplasia in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top